Proactiveinvestors USA & Canada Rhinomed Ltd https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Rhinomed Ltd RSS feed en Tue, 21 May 2019 06:05:17 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Rhinomed to launch vapour release technology after securing US purchase orders ]]> https://www.proactiveinvestors.com/companies/news/218640/rhinomed-to-launch-vapour-release-technology-after-securing-us-purchase-orders-218640.html Rhinomed Ltd (ASX:RNO) is set to launch its revolutionary ProntoTM rechargeable vapour release technology in the second half of 2019 targeting sleep and decongestion.

This follows the receipt of initial purchase orders from one of the USA’s leading drug store chains.

Pronto comes in two formulation variants - Pronto Sleep and Pronto Clear - aimed at addressing unmet needs in the US$49 billion global sleep aid market and US$34 billion global nasal congestion, cough, cold and allergy market.

Initial purchase orders

The initial purchase orders for the Pronto Sleep aid product have been received from one of America’s leading drugstore chains with product shipping scheduled for the end of May 2019 for more than 2,800 packs, which will be rolled out into 900 stores.

This purchase order is also from a stockist of the company's Mute technology.

Based on stenting technology

Based on the company’s existing BreatheAssistTM stenting technology, which has seen the release of two variants MuteTM and TurbineTM, the new Pronto range includes the novel AirstreamTM release system.

This allows a specific amount of a formulation to be released into the nasal airstream over a set period of time.

By combining this new vapour release technology with the Mute’s stenting action, Rhinomed provides users with a unique dual action medical device that not only improves nasal airflow, but also delivers the associated benefits of the specific formulation.

"World leading investor"

Rhinomed chief executive officer Michael Johnson said: “Rhinomed is delivering on its potential as a world-leading investor in the nasal, respiratory, sleep and drug delivery markets.

“We have become one of those rare Australian companies that has not only developed a technology but has also now proven consumer and clinical adoption, established global distribution and shelf presence and established a product that is now one of the fastest growing brands in its category.

“Mute has now successfully delivered millions of nights of better sleep to customers across three continents – it's time we start leveraging our platform to deliver drugs and formulations into specific target markets.”

]]>
Tue, 16 Apr 2019 15:33:00 -0400 https://www.proactiveinvestors.com/companies/news/218640/rhinomed-to-launch-vapour-release-technology-after-securing-us-purchase-orders-218640.html
<![CDATA[News - Rhinomed Limited gets ready to raise ]]> https://www.proactiveinvestors.com/companies/news/142773/rhinomed-limited-gets-ready-to-raise-64549.html Technology firm Rhinomed Limited (ASX:RNO) has been granted a trading halt by the ASX, pending details of a capital raising.

The company has a very unique focus on nasal, respiratory and breathing management technologies, and is focussed on monetising applications for markets including sleep, wellbeing, drug delivery and sport.

Earlier in the month the company entered into a landmark partnership with SleepGP, a growing network of GP practices, to raise awareness of sleep disordered breathing issues within the family medicine setting.

Rhinomed's Mute™ is a unique nasal respiratory technology that has been found to reduce the volume and frequency of snoring in 75% of users.

The halt will remain in place until the opening of trade on Friday 18th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 16 Sep 2015 10:30:00 -0400 https://www.proactiveinvestors.com/companies/news/142773/rhinomed-limited-gets-ready-to-raise-64549.html
<![CDATA[News - Rhinomed Limited to update on first stage of global pharmacy distribution ]]> https://www.proactiveinvestors.com/companies/news/142771/rhinomed-limited-to-update-on-first-stage-of-global-pharmacy-distribution-64076.html Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to the first stage in global pharmacy distribution.

The halt will last until the earlier of the announcement being made or the start of trade on Friday, 21st August 2015.

In the June 2015 Quarter, the company reported receipts from customers of $192,000, an increase of $33,000 from the previous quarter due to growing demand for its Turbine sports breathing device.

Sales in FY2016 are expected to increase due to expanded global distribution of Turbine. It has also received early demand for its Mute snoring and sleep technology.

Rhinomed had $1.37 million in cash as at 30th June 2015.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Wed, 19 Aug 2015 14:30:00 -0400 https://www.proactiveinvestors.com/companies/news/142771/rhinomed-limited-to-update-on-first-stage-of-global-pharmacy-distribution-64076.html
<![CDATA[News - Rhinomed sits atop Friday’s most traded ]]> https://www.proactiveinvestors.com/companies/news/142769/rhinomed-sits-atop-fridays-most-traded-62400.html Friday’s leading volume stocks on the ASX.

NameCodeLastChangeVolume Rhinomed ASX:RNO $0.052 92.6% 201,094,982 Collaborate Corp ASX:CL8 $0.038 -5% 27,035,631 Resmed Inc ASX:RMD $6.99 3.9% 26,895,241 Lynas Corporation ASX:LYC $0.044 -8.3% 22,371,166 Telstra Corporation ASX:TLS $6.20 0.8% 19,926,793 Eden Energy ASX:EDE $0.014 16.7% 19,924,909 Metcash Limited ASX:MTS $1.44 12.1% 18,719,733 Activistic Limited ASX:ACU $0.18 0% 17,162,582 Environmental Clean Technologies ASX:ESI $0.015 0% 16,759,616 FAR Limited ASX:FAR $0.088 -6.4% 16,006,613

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 18 May 2015 08:00:00 -0400 https://www.proactiveinvestors.com/companies/news/142769/rhinomed-sits-atop-fridays-most-traded-62400.html
<![CDATA[News - Rhinomed Limited in halt on European sales of snoring product ]]> https://www.proactiveinvestors.com/companies/news/142767/rhinomed-limited-in-halt-on-european-sales-of-snoring-product-62369.html Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to European sales of its Mute over-the-counter snoring product.

The halt will last until the earlier of the announcement being made or the start of trade on Monday, 18th May 2015.

In April, the company expand its Australian wholesale pharmacy distribution footprint with Sigma Pharmaceuticals Limited (ASX:SIP) to include Mute.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 15 May 2015 06:30:00 -0400 https://www.proactiveinvestors.com/companies/news/142767/rhinomed-limited-in-halt-on-european-sales-of-snoring-product-62369.html
<![CDATA[News - Rhinomed Limited to advance distribution of snoring product ]]> https://www.proactiveinvestors.com/companies/news/142765/rhinomed-limited-to-advance-distribution-of-snoring-product-61508.html Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to the appointment of an Australian Pharmacy Distribution group for its Mute over-the-counter snoring product.
   
The halt will last until the earlier of the announcement being made or the start of trade on Wednesday, 1st April 2015.

Independent user trial results (conducted November 2014) confirmed the efficacy of Mute with 75% of respondents reported a reduction in snoring.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Mon, 30 Mar 2015 13:30:00 -0400 https://www.proactiveinvestors.com/companies/news/142765/rhinomed-limited-to-advance-distribution-of-snoring-product-61508.html
<![CDATA[News - Rhinomed Limited to increase cash position ]]> https://www.proactiveinvestors.com/companies/news/142763/rhinomed-limited-to-increase-cash-position-57209.html Medical technology company Rhinomed Limited (ASX:RNO) is heading to market with a capital raising.

The ASX has granted the company a trading halt, with its shares placed in pre-open.

Earlier in the month the company appointed

Australian based EI Trading and its Israeli subsidiary AirActive as inaugural distribution partner for its Turbine nasal dilation device in Israel.

The deal seeks to introduce the Turbine range of technologies into the Israeli cycling and triathlon community and place the Turbine into over 450 Israeli cycling retailers.

Rhinomed is focused on producing leading technologies and launching these into the international marketplace.

Last month, the Turbine was granted registration with the US Food and Drug Administration as a medical device.

The Turbine is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a solution to breathlessness during aerobic exercise.

The halt will remain in place until the opening of trade on Monday 1st September 2014, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 28 Aug 2014 10:00:00 -0400 https://www.proactiveinvestors.com/companies/news/142763/rhinomed-limited-to-increase-cash-position-57209.html
<![CDATA[News - Rhinomed expands nasal dilation device into Israel ]]> https://www.proactiveinvestors.com/companies/news/142761/rhinomed-expands-nasal-dilation-device-into-israel-57071.html Rhinomed (ASX:RNO) should trade firmer after appointing Australian based EI Trading and its Israeli subsidiary AirActive as inaugural distribution partner for its Turbine nasal dilation device in Israel.

The deal seeks to introduce the Turbine range of technologies into the Israeli cycling and triathlon community and place the Turbine into over 450 Israeli cycling retailers.

Rhinomed is focused on producing leading technologies and launching these into the international marketplace.

Air Active has a strong relationship with the Israeli Pharmacy sector and will be utilising this network, alongside its partnership with leading bike retailers to grow the presence of the Turbine range in Israel.

A distributor with strong links into pharmacy retailers puts in place the foundations for extending the agreement to our sleep apnea range of products which Rhinomed is on track to launch later this year.

Last month, the Turbine was granted registration with the US Food and Drug Administration as a medical device.

The Turbine is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a solution to breathlessness during aerobic exercise.

A recent independent high performance product trial showed that 66% of professional riders increased their power output at an average of 6.5%.

 US FDA registration of the Turbine is an important step in allowing the Turbine to enter the giant US market with premium positioning as a FDA class 1 medical device in the US.

The Turbine is currently sold on line and at selected retail outlets in Australia.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 21 Aug 2014 12:30:00 -0400 https://www.proactiveinvestors.com/companies/news/142761/rhinomed-expands-nasal-dilation-device-into-israel-57071.html
<![CDATA[News - Rhinomed wins FDA approval for nasal dilator ]]> https://www.proactiveinvestors.com/companies/news/142759/rhinomed-wins-fda-approval-for-nasal-dilator-56356.html Rhinomed's (ASX:RNO) sport technology the Turbine was granted registration with the US Food and Drug Administration as a medical device.

The Turbine™ is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a solution to breathlessness during aerobic exercise.

A recent independent high performance product trial was carried out by former Olympic Cyclist, Rob Crowe, which showed that 66% of professional riders increasing their power output at an average of 6.5%.

Successfully granting US FDA registration of the Turbine is an important step in allowing the Turbine™ to enter the giant US market with premium positioning as a FDA class 1 medical device in the US.

The Turbine is currently sold on line and at selected retail outlets in Australia.

Registration granted to the Turbine by the US FDA allows the company to have a much wider range of discussions with US based retailers and wholesalers.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 18 Jul 2014 10:30:00 -0400 https://www.proactiveinvestors.com/companies/news/142759/rhinomed-wins-fda-approval-for-nasal-dilator-56356.html
<![CDATA[News - Rhinomed shares jump 75% on enhanced breathing device enthusiasm ]]> https://www.proactiveinvestors.com/companies/news/142758/rhinomed-shares-jump-75-on-enhanced-breathing-device-enthusiasm-56067.html Rhinomed (ASX:RNO) shares have traded 75% higher today, hitting an intraday high of $0.043 after closing yesterday at $0.024.

Shares in the company last traded at $0.038.

Rhinomed manufactures and sells its Turbine enhanced breathing device which purportedly increases the amount of air and oxygen that can pass through the nasal passages and into the lungs.

It is being targeted for use in athletes and particularly cyclists.

In early June, the company reported that it had now attracted 13,152 new subscribers to its subscriber database.

The broader drive through both online and offline media, including campaigns with bikeexchange.com.au and firstoffthebike.com is exposing the Turbine brand to ‘qualified’ cyclists’ and athletes.

All those who have joined the Turbine subscriber base have expressed high-level interest in cycling and are now being introduced to the benefits of the Turbine.

The recent Ridewiser Trial results showed some Turbine users could generate an additional 6.5% in power, and Rhinomed has been working with Tour de France green jersey winner Baden Cooke in Europe to introduce the Turbine to the world’s leading cyclists and teams.

The company has also enlisted Giant Bike stores and Bicycles Inc. as Australian retail outlets.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 04 Jul 2014 14:30:00 -0400 https://www.proactiveinvestors.com/companies/news/142758/rhinomed-shares-jump-75-on-enhanced-breathing-device-enthusiasm-56067.html
<![CDATA[News - Rhinomed achieves 10,000 subscribers for enhanced breathing device ]]> https://www.proactiveinvestors.com/companies/news/142756/rhinomed-achieves-10000-subscribers-for-enhanced-breathing-device--55460.html Rhinomed (ASX:RNO) has exceeded the milestone target of a subscriber base of 10,000 people for its Turbine enhanced breathing device.

The company has now attracted 13,152 new subscribers to its subscriber database.

Growth in the subscriber base reflects the concerted marketing and promotional push by the company over the last quarter.

The broader drive through both online and offline media, including campaigns with bikeexchange.com.au and firstoffthebike.com is exposing the Turbine brand to ‘qualified’ cyclists’ and athletes.

All those who have joined the Turbine subscriber base have expressed high-level interest in cycling and are now being introduced to the benefits of the Turbine.

The recent Ridewiser Trial results that showed some Turbine users could generate an additional 6.5% in power have generated interest in the Turbine.

Rhinomed has been working closely with Tour de France green jersey winner Baden Cooke in Europe to introduce the Turbine to the world’s leading cyclists and teams.

The company has also enlisted Giant Bike stores and Bicycles Inc. as retail outlets.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 05 Jun 2014 16:40:00 -0400 https://www.proactiveinvestors.com/companies/news/142756/rhinomed-achieves-10000-subscribers-for-enhanced-breathing-device--55460.html
<![CDATA[News - Rhinomed Limited to bank R&D tax refund for BreatheAssist™ technology ]]> https://www.proactiveinvestors.com/companies/news/142754/rhinomed-limited-to-bank-rd-tax-refund-for-breatheassist-technology-53304.html Rhinomed Limited (ASX:RNO) expects to receive a cash refund of about $388,000 from the Australian Government’s Research and Development Tax Incentive Program.

This will be used to support the continued development of its BreatheAssist™ technology.

It had earlier this month raised $2.5 million through a private placement of 60 million shares priced at $0.042 each.

The company is set to tap the US$3.6 billion migraine drug market by developing a drug to be delivered via its proprietary nasally delivered BreatheAssist technology.

It will develop a variant of its nasal and respiratory delivery system that will contain low dose of Sumtriptan to treat acute migraine. Its nasal technology already has wide acceptance within the sporting environment.

The halt will remain in place until the opening of trade on Thursday 20th February 2014, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news,articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 28 Feb 2014 18:20:00 -0500 https://www.proactiveinvestors.com/companies/news/142754/rhinomed-limited-to-bank-rd-tax-refund-for-breatheassist-technology-53304.html
<![CDATA[News - Rhinomed Limited heads to market for capital raising ]]> https://www.proactiveinvestors.com/companies/news/142752/rhinomed-limited-heads-to-market-for-capital-raising-52925.html Rhinomed Limited's (ASX: RNO) shares are in pre-open this morning following the Australian Stock Exchange granting the company a trading halt.

Rhinomed requested the halt pending capital raising details.

The company is set to tap the US$3.6 billion migraine drug market by developing a drug to be delivered via its proprietary nasally delivered BreatheAssist technology.

It will develop a variant of its nasal and respiratory delivery system that will contain low dose of Sumtriptan to treat acute migraine. Its nasal technology already has wide acceptance within the sporting environment.

The halt will remain in place until the opening of trade on Thursday 20th February 2014, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news,articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Tue, 18 Feb 2014 11:00:00 -0500 https://www.proactiveinvestors.com/companies/news/142752/rhinomed-limited-heads-to-market-for-capital-raising-52925.html
<![CDATA[News - Rhinomed to develop drug for acute migraine ]]> https://www.proactiveinvestors.com/companies/news/142750/rhinomed-to-develop-drug-for-acute-migraine-52834.html Rhinomed (ASX:RNO) is set to tap the US$3.6 billion migraine drug market by developing a drug to be delivered via its proprietary nasally delivered BreatheAssist technology.

It will develop a variant of its nasal and respiratory delivery system that will contain low dose of Sumtriptan to treat acute migraine. Its nasal technology already has wide acceptance within the sporting environment.

Rhinomed is commercialising its BreatheAssist technology in the sport, well-being, sleep and drug delivery markets and has developed a product called Turbine for athletes that has been shown to increase airflow by an average of 38% through nasal passages.

Administering the drug nasally provides faster and more convenient uptake and fewer side effects compared with oral or injection therapies.

The migraine market is huge with over 37 million Americans estimated to be suffering from it.

Rhinomed had over $742,000 in cash in the last quarter and access to facility of over $5.2 million. It is likely to receive an R&D tax incentive rebate of around $388,393 in the quarter ending March 2014.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 14 Feb 2014 13:20:00 -0500 https://www.proactiveinvestors.com/companies/news/142750/rhinomed-to-develop-drug-for-acute-migraine-52834.html
<![CDATA[News - Rhinomed research study confirms U.S. opportunity for nose airflow respiratory device ]]> https://www.proactiveinvestors.com/companies/news/142748/rhinomed-research-study-confirms-us-opportunity-for-nose-airflow-respiratory-device-52619.html Rhinomed (ASX:RNO) has completed a market research study surveying 1,000 professional and amateur athletes in the U.S. that confirm that a market opportunity exists for its Turbine™ respiratory sport technology device.

Turbine, which seeks to increase airflow through the nose, is purported to increase airflow by up to 38% and has been trialed and used by leading professional cyclists, including Mark O’Brien and Australian Olympian cyclist Rob Crowe.

Notably, the study found that 76% of the participants focused on breathing through the nose during their sporting activities while 83% would likely or very likely trial Turbine.

In addition, 78% believe Turbine will make breathing easier during strenuous activity.

The research involved the recruitment of 1000 committed athletes (both professional and amateur) who are training for more than 8 hours a week and preparing for, or competing in, upcoming events.

It was both qualitative and quantitative in nature, specifically evaluating responses to the Turbine proposition and reaction to the Turbine compared with existing solutions.

Turbine targets the billion dollar Australian sport and exercise market, particularly the cycling, triathlon, running and aerobic sport markets.

It will then expand its reach globally through international affiliate sites and distribution channels in 2014.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Fri, 07 Feb 2014 12:20:00 -0500 https://www.proactiveinvestors.com/companies/news/142748/rhinomed-research-study-confirms-us-opportunity-for-nose-airflow-respiratory-device-52619.html
<![CDATA[News - Rhinomed's respiratory device increase airflow through the nose ]]> https://www.proactiveinvestors.com/companies/news/142747/rhinomeds-respiratory-device-increase-airflow-through-the-nose-50399.html Medical technology company Rhinomed (ASX: RNO) has released its inaugural product Turbine™, which increases airflow through the nose.

The respiratory sport technology device is purported to increase airflow by up to 38% and has been trialed and used by leading professional cyclists, including Mark O’Brien and Australian Olympian cyclist Rob Crowe.

This targets the billion dollar Australian sport and exercise market, particularly the cycling, triathlon, running and aerobic sport markets.

It will then expand its reach globally through international affiliate sites and distribution channels in 2014.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

]]>
Thu, 21 Nov 2013 08:40:00 -0500 https://www.proactiveinvestors.com/companies/news/142747/rhinomeds-respiratory-device-increase-airflow-through-the-nose-50399.html